Results 131 to 140 of about 113,416 (261)

Transurethral ultrasound ablation (TULSA) for prostate cancer: a systematic review and meta‐analysis

open access: yesBJU International, EarlyView.
Objective Our objective was to synthesise evidence on oncological, functional and safety outcomes of magnetic resonance imaging‐guided transurethral ultrasound ablation (TULSA) for primary and recurrent prostate cancer. Methods MEDLINE, Embase, Web of Science and Scopus were systematically searched from inception to July 2025. The primary outcomes were
Eugene Wang   +4 more
wiley   +1 more source

Opposing roles of acid phosphatase 1 (ACP1) and ACP3 in prostate cancer progression

open access: yesBJU International, EarlyView.
Objectives To evaluate the roles of intracellular acid phosphatase 1 (ACP1) and ACP3 expression as biomarkers of prostate cancer progression through a systematic review and meta‐analysis assessing associations with disease presence, tumour aggressiveness, and patient prognosis.
Alessandra V. de S. Faria   +3 more
wiley   +1 more source

Notoginsenoside‐Fa mitigates vascular endothelial permeability via targeting SUGT1 to stabilize NLRP3 in a resting state

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Notoginsenoside‐Fa (Noto‐Fa) is an emerging active compound derived from notoginseng with promise in treating cardiovascular diseases. The development of cardiovascular diseases is intricately linked to the damage of vascular endothelium and it is widely acknowledged that numerous chronic inflammation pathways, especially the ...
Xiao‐Ying Yu   +9 more
wiley   +1 more source

Outcomes for post‐transplant relapsed acute lymphoblastic leukaemia in the era of novel therapies: A retrospective multicentre UK study

open access: yes
British Journal of Haematology, EarlyView.
Alexandros Rampotas   +16 more
wiley   +1 more source

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli   +4 more
wiley   +1 more source

Treatment‐Free Remission in Chronic Myeloid Leukemia: Toward Precision and Personalized Approaches to Functional Cure

open access: yesCancer Science, EarlyView.
Immune surveillance of residual leukemic stem cells after tyrosine kinase inhibitor discontinuation involves coordinated NK‐cell, CTL, Treg, pDC, and neutrophil activity that predicts treatment‐free remission, while exhausted CTLs and Treg expansion predict relapse in chronic myeloid leukemia.
Hiroshi Ureshino, Shinya Kimura
wiley   +1 more source

Home - About - Disclaimer - Privacy